Top Injectable Manufacturer in Mauritania – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 hour ago
- 10 min read
Last Updated: August 27, 2026
TL;DR: Mauritania imports essentially all of its medicines, and the route in is narrower and more specific than most exporters expect. A marketing authorisation, the Autorisation de Mise sur le Marche, is granted by the Minister of Health under Loi n° 2004/036 and is valid for five years; the same law carves out a separate, fee-exempt registration procedure for essential medicines selected through public tender, which is the door most volume actually walks through. That tender is run by CAMEC, the state purchasing centre, and its 2025 international call prequalified product-and-manufacturer pairs for a three-year approval with physical samples required at submission. The law also requires the importing company to be pharmacist-owned with a legally liable pharmacien responsable, so a foreign manufacturer cannot import on its own account. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the sample, analytical and stability package that a Mauritanian partner needs to enter that tender credibly.
Key Takeaways
The tender route is a separate legal pathway, not a shortcut through the normal one. Article 26 of Loi n° 2004/036 requires an Autorisation de Mise sur le Marche before any medicine may be imported, sold or even distributed free of charge – and then states in the same article that essential medicines selected through a public tender procedure are registered under a separate procedure fixed by the Minister and are exempt from registration fees. For a generic injectables manufacturer that single sentence reorders the whole commercial plan: the question is not only how to register, but whether the molecule is on the national essential medicines list and inside a CAMEC tender cycle.
CAMEC prequalifies the product and the factory together, for three years at a time. Its 2025 international call, reference AOIPQ N°2025/001/CAMEC, was explicitly a prequalification of suppliers of essential generic medicines under INN and of medical consumables, building a validated list of product-and-manufacturer couples. The approval runs three years and lets the holder bid in restricted consultations during that period. Physical samples had to accompany the prequalification dossier. A manufacturer that cannot supply representative samples and defend them analytically does not get onto the list, and being off the list means being invisible for three years.
You cannot import into Mauritania on your own account. Articles 44 and 48 of the same law require every pharmaceutical import and wholesale establishment to hold an opening authorisation from the Minister of Health, to be owned by one or more pharmacists or to be a company in whose capital Mauritanian pharmacists may hold a share, and to have a pharmacien responsable as technical director on a Ministry model contract, personally liable. Each separate establishment needs its own authorisation and its own pharmacien delegue. The practical consequence is that the quality of your Mauritanian partner is part of your regulatory file, not a separate commercial question.
Much of the operating detail is simply not published, and honest suppliers say so. Article 28 leaves the actual conditions for granting an authorisation to a ministerial arrete, and that arrete is not publicly available; nor is the fee schedule, nor a review timeline, nor a published register of authorised medicines. Mauritania has not signed the African Medicines Agency treaty and its regulator has not been benchmarked under the WHO maturity framework, and because Mauritania left ECOWAS in 2000 it is outside the WAHO/ECOWAS medicines harmonisation work as well. Any supplier quoting you a confident Mauritanian dossier format or approval time is quoting something they cannot source.
Introduction: Why Mauritania Demands a Premium Injectable Manufacturer in Mauritania
Mauritania is a country of about 5.3 million people with a gross national income per head of roughly US$2,210, spending around 4.34 per cent of GDP on health, or about US$92 per person per year, with close to 44 per cent of that coming straight out of patients' pockets – all World Bank figures, the health-spending ones for 2023. Those numbers set the commercial temperature of the market. It is a price-sensitive, tender-led, public-sector-dominated environment, and it is one where a supplier's landed cost matters as much as its dossier. It is also a market with no publicly documented domestic sterile manufacturing: a 2022 investment convention for a first pharmaceutical plant in Nouakchott was announced by the government, but nothing published confirms it was built or licensed, and the country continues to import.
The clinical demand is real and it is disproportionately injectable. WHO's 2024 malaria country profile for Mauritania, with data validated by the country in November 2024, records that 64 per cent of the population – about 3.2 million people – live in high-transmission areas, that 108,415 presumed and confirmed cases were reported against a WHO estimate of 192,600, and that national policy for severe malaria is injectable artesunate. Maternal mortality stood at 381 per 100,000 live births in 2023, which translates into demand for oxytocics, magnesium sulphate, antibiotics and resuscitation fluids. And in September 2025 the Ministry of Health confirmed the award of what regional press described as the country's first international tender dedicated to haemodialysis, a grouping of Japan's NIPRO with the Mauritanian company NOSOMACI, an investment reported at more than six million euros in a segment the same reporting described as previously under monopoly and little modernised. Sterile injectables sit in the middle of all of it.
What Sets a World-Class Injectable Manufacturer in Mauritania Apart
The first differentiator is knowing which of the two doors you are walking through. The normal route is the Autorisation de Mise sur le Marche granted by the Minister of Health, valid five years and renewable, with any variation however minor requiring prior authorisation. Applications are assessed with the advice of the Commission Nationale des Medicaments, whose statutory criteria under Article 21 are unusually explicit about commerce as well as science: therapeutic interest and efficacy, safety in normal use, quality, the ex-works wholesale price in the exporting country, and whether the product holds an authorisation in its country of origin – with that last requirement expressly waived for generics. A manufacturer that arrives with a defensible Indian price position and a clean generic story is answering the question the Commission is actually asked.
The second is understanding what a refusal looks like, because the law tells you. Article 30 requires any refusal to be reasoned and notified within thirty days, and lists among the grounds that the manufacturing and control conditions are not compliant, or that the methods of manufacture and control are inadequate to guarantee quality at batch scale. That is a manufacturing-capability test, not a paperwork test. It is reinforced downstream by Article 126, which requires pharmacy inspection to visit every establishment at least once a year. A supplier whose batch records, process validation and analytical method validation would survive that reading is a supplier whose file is difficult to refuse on the stated grounds.
Quality Systems Behind Every Injectable Supplied to Mauritania
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Environmental monitoring, operator qualification, media fills, filter integrity testing and container-closure integrity are run as a continuous programme rather than as a batch-release afterthought. Finished product is released against IP, USP, BP and EP monographs using HPLC and GC for assay and related substances, Karl Fischer for water content where the presentation demands it, and LAL for bacterial endotoxins, with sterility testing on every sterile lot. The reason this matters specifically for Mauritania is CAMEC: a prequalification in which physical samples are submitted alongside the dossier is decided partly on what the vial does in a laboratory, not only on what the file says about it.
Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B, in the actual container-closure system that will ship, and defended on hot and dry conditions appropriate to Saharan storage and long overland distribution rather than on temperate data borrowed from another market. Because Mauritania has published no dossier format, we build the file so that it can be presented in CTD or ACTD structure on request and reorganised into whatever the Ministry's arrete specifies once it is seen, rather than assuming a format and having to rebuild. Certificates of analysis, the manufacturing licence and the WHO-GMP certificate are issued in a form that survives chamber of commerce, Ministry of External Affairs and embassy legalisation without needing reissue.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Mauritania for Global Buyers
The commercially decisive fact about Mauritania is that one buyer shapes the market. CAMEC – the Centrale d'Achat des Medicaments, Equipements et Consommables Medicaux – was created by decree in 2002 as a mixed-economy company and converted by decree in 2010 into a wholly state-owned societe nationale with a capital of 137,025,000 MRU, operating on a non-profit cost-recovery basis with its own special procurement commission. Its public catalogue distinguishes monopoly medicines, essential medicines and consumables. Alongside the three-yearly prequalification it publishes a running stream of ad-hoc award records through 2026, which tells a supplier something useful: there is off-cycle business, and being prequalified is what makes you reachable when it appears.
India is already a substantial supplier and the relationship is commercial rather than treaty-based, which is worth stating plainly because it is often implied otherwise. On UN Comtrade figures India exported about US$10.5 million of HS Chapter 30 pharmaceutical products to Mauritania in 2024 and about US$11.9 million in 2025. The Embassy of India in Nouakchott, which opened in June 2021, records in its bilateral brief of 9 June 2025 that President Droupadi Murmu made the first-ever State visit to Nouakchott in October 2024 and lists the four bilateral agreements in force – a diplomatic visa waiver, a foreign-office consultations protocol, a diplomatic-training memorandum and a cultural exchange programme. There is no pharmaceutical or regulatory memorandum between the two countries. Nothing about being Indian shortens a Mauritanian file; what shortens it is the file itself.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which suits a market where the same molecule may need to serve a CAMEC tender line under INN and a private importer's own-label presentation at the same time. We supply dry powder vials, liquid ampoules and vials, lyophilised presentations and small-volume parenterals across anti-infectives, analgesia, anaesthesia, oncology support, emergency and critical care; we support own-label and technology-transfer programmes; and we prepare CTD and ACTD dossiers, DMF and CEP-referenced API documentation, and legalisation-ready certification for more than 30 export markets. For a Mauritanian importer the practical offer is a partner who can produce representative samples on request, defend them against a monograph, and hold the specification steady across a three-year prequalification window.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates medicines and injectables in Mauritania?
The Ministry of Health. Under Loi n° 2004/036 the Autorisation de Mise sur le Marche is granted by the Minister of Health, on the advice of the Commission Nationale des Medicaments, whose secretariat is the pharmacy directorate and whose membership includes the Inspector General of Health, the director responsible for pharmacy and representatives of the national professional order. Note that the directorate's name appears differently in different official sources – the Ministry's own site uses Direction de la Pharmacie et des Laboratoires, while the African Medicines Agency's published ratification dataset records it as Direction du Medicament et des Laboratoires – and we have not found a decree that settles it. Inspection sits with the Inspection Generale de la Sante, which is required to visit every establishment at least annually.
How long does a Mauritanian marketing authorisation last, and what does it cost?
The authorisation is valid for five years and is renewable, and any variation, however minor, requires prior authorisation. On cost we will not give you a number. Article 29 provides that the application carries a fee whose amount is fixed by a joint order of the Ministers of Health and Finance, and we could not locate that order or any published tariff. What the law does state clearly is that essential medicines selected through the public tender procedure are registered under a separate procedure and are exempt from registration fees, which is a material commercial difference between the two routes.
Does Mauritania require a CTD dossier, a WHO-GMP certificate or a WHO-type CoPP?
We cannot tell you, and neither can anyone else from published sources. Article 28 leaves the conditions for granting an authorisation to a ministerial order that is not publicly available, and the registration articles of the 2004 law do not themselves mention Good Manufacturing Practice certification, the WHO certification scheme or any dossier format. In practice a Mauritanian importer will ask for a WHO-GMP certificate and a certificate of pharmaceutical product because that is what regional practice and tender documents generally expect, and CAMEC's prequalification dossier is not published either. We supply both as a matter of course and build the technical file so it can be presented in CTD or ACTD structure. What we will not do is state a requirement we cannot source.
Can a foreign manufacturer import directly, or is a local partner required?
A local partner is effectively required. Articles 44 to 48 of Loi n° 2004/036 require every pharmaceutical import and wholesale establishment to hold an opening authorisation from the Minister of Health, and require that the company be owned by one or more pharmacists, or be a commercial company in whose capital Mauritanian pharmacists may hold a share, with a pharmacien responsable as technical director on a Ministry model contract who is personally liable. Every separate establishment needs its own authorisation and its own delegated pharmacist, and importers may supply only other authorised wholesalers or persons licensed to dispense. Named-patient imports of unregistered medicines for serious disease, and donation imports, each require a specific authorisation from the director responsible for pharmacy.
What makes Farbe Firma a suitable injectable manufacturer for Mauritania?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Mauritania that translates into four concrete things. We can produce representative physical samples for a CAMEC prequalification and defend them against IP, USP, BP or EP monographs using validated HPLC, GC, Karl Fischer and LAL methods. We generate ICH Q1A(R2) and Q1B stability data on hot and dry conditions matched to Saharan storage and overland transit. We prepare CTD and ACTD dossiers and legalisation-ready certification that survives the chamber, ministry and embassy chain without reissue. And we hold a specification steady across a three-year prequalification window, which is what an approval tied to a product-and-manufacturer pair actually requires. Contact director@farbefirma.org to discuss a specific molecule, tender line or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments